News › Clinical Practice, Industry News, Patient Care

FDA approves first treatment for advanced form of the second most common skin cancer

September 28, 2018

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.
Libtayo works by targeting the cellular pathway known as PD-1 (protein found on the body’s immune cells and some cancer cells). By blocking this pathway, the drug may help the body’s immune system fight the cancer cells.
Read more at FDA.gov >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Sends Peptide ‘Interim Access Policy’ to White House for Review
    • New ACOG Menopause Guidelines Expand Hormone Therapy and Symptom Treatment Recommendations
    • Galderma to Acquire ZO Skin Health for $1.5 Billion
    • AscendPoint Agency Acquires Medical Marketing Whiz
    • PracticeQ Becomes Platinum Vendor Affiliate with the American Med Spa Association
Advertisement